BioAtla | Investor Presentation Deck | 43 slides · page 36 of 43
The slide outlines a dose-escalation study (3+3 design) leading to RP2D selection and subsequent expansion cohorts.
Pitch deck · roadmap · plan_implementation · dense density
Slide locked Sign in to view
Slide schematic 5/5
diagram 1/1 legend 1/1 list 2/2 title 1/1
Components 5
timeline legend bullet bullet headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1